CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the appointment of Marc Tessier-Lavigne, Ph.D., to its board of directors. Dr. Tessier-Lavigne is president of The Rockefeller University and formerly served as executive vice president for research and chief scientific officer at Genentech, where he directed 1,400 people in disease research and drug discovery in cancer, immune disorders, infectious diseases and neurodegenerative diseases.
